Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCLIN.L Share News (CLIN)

  • There is currently no data for CLIN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Rockhopper rises as Navitas enters project

Wed, 08th Dec 2021 11:45

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

----------

AIM - WINNERS

----------

Rockhopper Exploration PLC, up 22% at 6.38 pence, 12-month range 4.50p-12.50p. The oil & gas exploration and production company says Navitas Petroleum LP is to enter its Sea Lion oil project in the Falkland Islands. Navitas replaces Harbour Energy PLC as Rockhopper's partner in the project.

----------

Equals Group PLC, up 12% at 70.40p, 12-month range 26.10p-73.00. The fintech payments firm says it has "significantly exceeded" its full-year expectations for both adjusted earnings and revenue. Group revenue for the year to date is GBP40.4 million, up 51% from GBP26.8 million for the same period in 2020. The strong revenue performance means increased gross profit and earnings, and Equals says it has exceeded its own full-year profitability forecasts, but does not provide a figure.

----------

Clinigen Group PLC, up 10% at 901.00p, 12-month range 541.50p-912.00p. Shares hit 12-month high after the pharmaceuticals and services provider agrees to be taken private by European investment firm Triton Funds in a GBP1.2 billion deal. Under the terms, Clinigen shareholders will receive 883p a share in cash. This is a 41% premium to the ex-dividend closing share price on December 1, which was the last business day before takeover talks were first announced. Clinigen shareholders will also be entitled to receive the previously declared final dividend of 5.46p a share.

----------

AIM - LOSERS

----------

Byotrol PLC, down 16% at 4.22p, 12-month range 4.00p-7.70p. Shares in the antimicrobial technologies company hit fresh 12-month low after profit warning and says its first half performance was below expectations. For six months to September 30, swings to pretax loss of GBP141,000 from GBP1.0 million profit year before. "Whilst we expect to be both profitable and cash generative in the second half of the year, with these uncertainties it is difficult to predict the quantum at this juncture. At present we are expecting IP sales to offset the majority of the anticipated shortfall in profit on product sale, but projecting the timing of IP sales is even more uncertain, so we feel it prudent to now reduce market guidance for the current financial year," it says.

----------

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
18 Jun 2018 16:22

Abcam Appoints Former Celltech CFO As Non-Executive Chairman

LONDON (Alliance News) - Life sciences company Abcam PLC said Monday it has appointed the former chief financial officer of Celtech Group PLC as a non-executive chairman.Peter Allen is a at

Read more
8 May 2018 12:06

Benchmark Appoints Clinigen Founder And Former Boss As New Chairman

LONDON (Alliance News) - Benchmark Holdings PLC said Tuesday it appointed Peter George as chairman with immediate effect.George founded and was chief executive officer of FTSE-listed Group

Read more
19 Mar 2018 08:34

Clinigen To Run Vyxeos Managed Access Program For Jazz Pharmaceuticals

LONDON (Alliance News) - Pharmaceutical firm Clinigen Group PLC has been appointed by Nasdaq-listed Jazz Pharmaceuticals PLC to distribute Vyxeos via a managed access outside

Read more
25 Jan 2017 16:47

Clinigen profits rise by a third

(ShareCast News) - Global pharmaceutical and services company Clinigen Group provided a trading update for the six months to 31 December on Wednesday, with gross profit up 34%. The AIM-traded firm said this was driven by a combination of "good" organic growth across all divisions, a full six months

Read more
18 Jan 2017 16:07

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
17 Jan 2017 14:10

Clinigen division teams up with TESARO

(ShareCast News) - Clinigen Group announced on Tuesday that its Idis Managed Access division has partnered with TESARO to launch a managed access program for the investigational PARP 1/2 inhibitor, niraparib. The AIM-traded company said Niraparib is being made available for eligible women in the U.S

Read more
9 Jan 2017 15:57

Clinigen enters into second agreement with Cumberland Pharmaceuticals

(ShareCast News) - Clinigen Group, an AIM listed global pharmaceutical and services company, and Cumberland Pharmaceuticals, a US specialty pharmaceutical company have entered into their second exclusive agreement to commercialise the oncology support drug Totect in the US. The first product Clinige

Read more
9 Jan 2017 14:51

Clinigen Group Gives Exclusive US Licence For Totect To Cumberland

Read more
15 Dec 2016 09:08

Clinigen to distribute BioQ's pain relief drug in Europe

(ShareCast News) - AIM-listed pharmaceutical Clinigen is to distribute BioQ Pharma's post-surgery pain management drug, Ropivacaine Readyfusor. The company's subsidiary Idis Global Access has agreed to supply and distribute the pre-filled Ropivacaine Readyfusor for post-operative pain management in

Read more
15 Dec 2016 07:58

Clinigen's Idis Signs Distribution Deal With BioQ Pharma

Read more
1 Dec 2016 11:03

Clinigen and Eisai launch breast cancer treatment in South Africa

(ShareCast News) - Pharmaceutical companies Clinigen and Eisai launched an advanced breast cancer treatment for women in South Africa called Halaven (eribulin). The treatment will benefit around 7,000 women in South Africa that are diagnosed with breast cancer each year. Halaven is now registered b

Read more
1 Dec 2016 07:53

Clinigen's Halaven Breast Cancer Drug Registered In South Africa

Read more
14 Nov 2016 15:07

Director dealings: Clinigen's Bacon slices off a chunk

(ShareCast News) - Clinigen Group director John Bacon has sold £1.4m of the pharmaceuticals and clinical trial services group. Bacon sold 200,000 shares at a price of 717p apiece, but still holds 730,767 shares in the company. He had originally joined the board as a non-executive director last year

Read more
11 Nov 2016 13:40

Clinigen says trading in-line for current FY

(ShareCast News) - Global pharmaceutical and services company Clinigen Group said its trading for the current financial year is in-line with directors' expectations. It said the year to 30 June marked the completion of its transformation into the global market leader in the management and supply of

Read more
11 Nov 2016 07:19

Clinigen Trading In Line With Good Organic, Acquisition-Driven Growth

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.